Chalcone derivatives ameliorate lipopolysaccharide-induced acute lung injury and inflammation by targeting MD2 - Zhang, Ya-li; Zhang, Wen-xin; Yan, Jue-qian; Tang, Ye-lin; Jia, Wen-jing; Xu, Zheng-wei; Xu, Ming-jiang; Chattipakorn, Nipon; Wang, Yi; Feng, Jian-peng; Liu, Zhi-guo; Liang, Guang (Acta pharmacologica Sinica, 2022)
Keywords: Acute Lung Injury - chemically induced; Acute Lung Injury - drug therapy; Administration, Oral; Animal models; Animals; Antibodies; Biomedical and Life Sciences; Biomedicine; Cells, Cultured; Chalcones - administration & dosage; Chalcones - pharmacology; Cytokines; Disease Models, Animal; Dose-Response Relationship, Drug; Edema; Humans; Immunology; Inflammation; Inflammation - chemically induced; Inflammation - drug therapy; Inflammatory diseases; Internal Medicine; Lipopolysaccharides; Lungs; Lymphocyte Antigen 96 - antagonists & inhibitors; Lymphocyte Antigen 96 - metabolism; Macrophages; Male; Medical Microbiology; Mice; Mice, Inbred C57BL; Molecular Structure; NF-κB protein; Oral administration; Permeability; Pharmaceutical sciences; Pharmacology/Toxicology; Phosphorylation; Respiratory distress syndrome; Respiratory failure; Structure-Activity Relationship; Surface plasmon resonance; TLR4 protein; Toll-Like Receptor 4 - antagonists & inhibitors; Toll-Like Receptor 4 - metabolism; Toll-like receptors; Vaccine; myeloid differentiation 2; lipopolysaccharide; inflammation; chalcone derivatives; mouse peritoneal macrophages; acute lung injury